“It’s an honor to be named in the Dow Jones Sustainability Indices for a ninth consecutive year. I am particularly proud of our team’s pr...
Omniose, a preclinical stage biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca for the search for potential vacc...
- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust imm...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
QIAGEN announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business. These inve...
QIAGEN to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region QIAGEN signed Memor...
CG Life’s fresh new look and feel embodies how everything the agency does with its client partners is shaped by the profound impact of science on eve...
Inaugural strategy is one of the largest ever first-time private life sciences growth funds Fundraise closed above its original target, reflecting stron...
Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces that it has acquired Replace Therapeutics Inc., a private biote...
SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD...
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neur...
"Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this sp...
This investment opportunity offers a unique chance for individuals and institutions to actively participate in the growth and transformation of the healthc...
The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two...
© 2024 Biopharma Boardroom. All Rights Reserved.
